Charles River Laboratories International has signed definitive agreements to sell its CDMO and Cell Solutions businesses to GI Partners, primarily for future contingent performance-based payments, and to sell certain European Discovery Services assets to IQVIA for about $145 million in cash plus up to $10 million in additional payments. The divestitures, expected to close in the second quarter of 2026, include CDMO sites in Tennessee, Maryland and the U.K., a Cell Solutions site in California, and five European discovery services sites. Charles River updated its 2026 outlook to reflect the deals, expecting reported revenue to fall by slightly more than $200 million while improving non-GAAP operating margin by at least 100 basis points and adding about $0.10 to non-GAAP EPS for the partial year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260224712091) on February 25, 2026, and is solely responsible for the information contained therein.